5 recruiting, 1 active not recruiting, 1 not yet recruiting. 4 Phase 1, 4 Phase 2, 1 Phase 3.
By phase and status
Follow Navlimetostat: new trials by email Literature Review of Navlimetostat trials Research Report on Navlimetostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]Navlimetostat (BMS-986504) in Healthy Female Participants
Navlimetostat, [14C]Navlimetostat - Healthy Female Participants | Phase 1 | Not yet recruiting | Bristol-Myers Squibb | 6 | 2026-09-16 | 2026-08-20 |
A Study of Navlimetostat (BMS-986504) Drug Interactions and Food Effect in Healthy Participants
Navlimetostat, Itraconazole, Rifampin - Healthy Female Adults | Phase 1 | Recruiting | Bristol-Myers Squibb | 80 | 2026-08-31 | 2026-10-05 |
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC - Solid Tumors | Phase 2 | Recruiting | Bristol-Myers Squibb | 260 | 2026-07-27 | 2026-10-06 |
Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer
Navlimetostat, Pumitamig - Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 17 | 2026-07-16 | 2026-09-25 |
A Phase 1 Study of Navlimetostat Tablet Formulations
Navlimetostat - Healthy Participants | Phase 1 | Recruiting | Bristol-Myers Squibb | 64 | 2026-04-27 | 2026-10-07 |
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Navlimetostat, Gemcitabine, Nab-paclitaxel - Pancreatic Ductal Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | Bristol-Myers Squibb | 470 | 2025-10-23 | 2026-06-03 |
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
BMS-986504, Izalontamab Brengitecan - Carcinoma, Non-Small-Cell Lung | Phase 2 | Recruiting | Bristol-Myers Squibb | 182 | 2025-09-09 | 2026-09-18 |
Conditions studied
Carcinoma, Non-Small-Cell Lung (2) · Pancreatic Neoplasms (2) · Brain Neoplasms (1) · Melanoma (1)
Sponsors
Bristol-Myers Squibb (6) · M.D. Anderson Cancer Center (1)
Countries
United States (6) · Canada (3) · China (3) · France (3) · Germany (3) · Italy (3) · Japan (3) · Spain (3) · Australia (2) · Belgium (2) · Hong Kong (2) · Ireland (2) · Netherlands (2) · Poland (2) · Romania (2)
Top investigators
Natalie Vokes, MD (1)
NIH funding
2025 (2)